Evidence-Based Benefits
- Superior to glucosamine + chondroitin — Lugo et al. (2016, n=191) found UC-II 40mg outperformed G+C (1,500mg+1,200mg) for WOMAC pain, stiffness, and physical function over 180 days
- Knee OA symptom reduction — Crowley et al. (2009, n=52) showed UC-II 40mg daily significantly reduced VAS pain scores by 40% vs. placebo in knee OA patients over 90 days
- Exercise-related joint support — Lugo et al. (2013, n=55) demonstrated UC-II improved knee extension range of motion and extended time to joint pain during exercise in healthy volunteers
- Immune modulation — UC-II works through oral tolerance in Peyer patches of the gut, training T-regulatory cells to suppress immune attacks on type II collagen in joints
- Convenient low dose — only 40mg daily required compared to multi-gram doses of other joint supplements, improving compliance